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KinaseMEK Kinase 2 (MEKK2) is a serine/threonine kinase that functions as aMAPK kinase kinase (MAP3K) to regulate
activation of Mitogen-activated Protein Kinases (MAPKs). We recently have demonstrated that ablation of
MEKK2 expression in invasive breast tumor cells dramatically inhibits xenograft metastasis, but the mechanism
by which MEKK2 inﬂuences metastasis-related tumor cell function is unknown. In this study, we investigate
MEKK2 function and demonstrate that silencing MEKK2 expression in breast tumor cell signiﬁcantly enhances
cell spread area and focal adhesion stability while reducing cell migration. We show that cell attachment to
thematrix proteins ﬁbronectin orMatrigel inducesMEKK2 activation and localization to focal adhesions. Further,
we reveal that MEKK2 ablation enhances focal adhesion size and frequency, thereby linking MEKK2 function to
focal adhesion stability. Finally, we show that MEKK2 knockdown inhibits ﬁbronectin-induced Extracellular
Signal-Regulated Kinase 5 (ERK5) signaling and Focal Adhesion Kinase (FAK) autophosphorylation. Taken
together, our results strongly support a role for MEKK2 as a regulator of signaling that modulates breast tumor
cell spread area and migration through control of focal adhesion stability.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Breast cancer progression fromprimary tumor tometastatic carcino-
ma requires that tumor cells attain the ability to detach from the prima-
ry tumor mass and move through surrounding tissue stroma to gain
access to distant tissues via the circulatory or lymphatic systems [1].
Therefore, tumor cell migration is absolutely essential for metastasis
to occur, and therapeutic intervention that blocks tumor cell migration
would be predicted to inhibit solid tumor metastasis. As with other
adherent cells, breast tumor cell migration requires the coordinated
initiation and release of adhesion to substrata [2]. Regulation of cell
adhesion to extracellular matrix proteins such as ﬁbronectin is accom-
plished through membrane-proximal protein complexes associated
with integrin receptors [3]. Integrins are dimeric cell membrane recep-
torswith extracellular domains that selectively bind to a range ofmatrix
protein ligands to elicit cellular responses [4]. The small integrin intra-
cellular domain functions as an anchor for the formation of multi-
protein complexes called focal adhesions that include the cytoskeletal
proteins actin, talin and vinculin along with signaling proteins in a
complex network estimated to include more than 180 protein–protein
interactions [5]. Focal adhesions link signaling proteins such as paxillin
and focal adhesion kinase (FAK) to integrin cytoplasmic domains and
thereby connect the intracellular tumor cell regulatory signaling to the
extracellular environment [6]. Thus focal adhesion complexes regulate., Maywood, IL 60153, USA.
ights reserved.cellmigration via control of adhesion, and factors that promote or inhib-
it focal adhesion stability or disassembly will strongly inﬂuence cell mi-
gration [6]. While numerous proteins have been shown to associate
with focal adhesion proteins in recent years [6,7], the understanding
of how signaling networks coordinate control of adhesion stability to
promote cell movement is incomplete.
Mitogen-activated protein kinases (MAPKs) are signaling regulators
that inﬂuence multiple cellular functions, including (but not limited to)
cell survival, differentiation, gene expression, and cell migration. MAPKs
have been categorized into four main groups, including ERK1/2, JNK,
p38 and ERK5, although multiple isoforms that expand the over number
to at least twelve member proteins have been identiﬁed [9]. MAPKs
are the terminal kinases of a three kinase activation cascade system in
which MAPKs are phosphorylated and consequently activated by a
MAPK kinase (MAP2K), which is itself phosphorylated and activated by
aMAPK kinase kinase (MAP3K). TheMAP3K class of MAPK regulators in-
cludes over twenty member proteins; more than the MAPK or MAP2K
protein groups combined. As the stimuli that activate each MAP3K can
vary widely, the relative abundance of distinct MAP3K proteins repre-
sents an important regulatory mechanism that contributes to the speci-
ﬁcity of MAPK activation. While the ERK1/2, JNK and p38 MAPK are all
responsive to activating signals originating from several different
MAP3K, ERK5 activity has been shown to be predominantly under the
control of only the MEKK2 andMEKK3members of the MAP3K class [9].
While similar in sequence (55% protein sequence identity) and
predicted domain structure, gene knockout studies indicate
that MEKK2 and MEKK3 have functionally distinct developmental
roles in mice [9]. MEKK3 knockout is associated with inadequate
946 A.A. Mirza et al. / Biochimica et Biophysica Acta 1843 (2014) 945–954angiogenesis, abnormal cardiac development and consequent embryo
lethality, whereas MEKK2 knockout mice are viable and fertile.
MEKK2 has been demonstrated to phosphorylate the MAP2K proteins
MKK4 and MKK7 that, in turn, phosphorylate and activate JNK. In addi-
tion to JNK regulation, MEKK2 can phosphorylate and activate the
MAP2K protein MEK5, that then phosphorylates and activates ERK5
[9]. In addition to the established regulatory roles in gene expression
and cell survival [10,11], JNK also has been linked to control of cell mi-
gration [12]. While multiple MAP3K proteins can inﬂuence JNK activa-
tion [9], suggesting that signiﬁcant functional redundancy exists
within this protein family, our group and others have found that indi-
vidual MAP3K signaling modules respond to different environmental
inputs to speciﬁcally control JNK activation. For example, c-Kit-
induced JNK activation in stem cell-derived mast cells requires
MEKK2, but not related kinase MEKK1 [13], whereas FGF-2 induces
JNK-dependent uPA expression in ﬁbroblasts that is blocked by ablation
of MEKK1, but not MEKK2 [14]. How MEKK2 speciﬁcally regulates JNK
activity to inﬂuence tumor cell biology has not been investigated, and
the tumor cell functions controlled by MEKK2 have not been deﬁned.
While JNK regulation and function have been extensively examined,
the current understanding of ERK5 is farmore limited. Knockout studies
have linked ERK5 to vascular and cardiac development [15,16], and
thus functional analysis of ERK5 in tumor cells has focused on the im-
portance of ERK5-dependent gene expression in tumor vascularity
and angiogenesis. Interestingly, Sawhney and colleagues found that
ERK5 co-immunoprecipitates with integrins and promotes FAK auto-
phosphorylation and consequent activation in invasive tumor cells
[17], linking ERK5 to cell adhesion and migration. However, the sig-
naling mechanisms that mediate ERK5 activity in these complexes
were not deﬁned.
Some of the cellular functions under the control of MAPK
signaling, including cell migration inﬂuence the course of solid
tumor progression and metastasis. We have recently conducted an
shRNA screen of MAP3Ks to identify potential metastasis regulators,
and we reported that silencing MEKK2 expression in breast tumor
cells dramatically inhibits metastasis arising from breast tumor
xenografts, whereas silencing MEKK3 did not reduce metastasis [8].
To understand the role of MEKK2 in solid tumor progression, our
subsequent studies have focused on deﬁning the mechanisms by
which MEKK2 breast tumor cell biology. In this report, we reveal
that MEKK2 regulates breast tumor cell migration, at least in part,
through control of focal adhesion stability. Furthermore, we demon-
strate that MEKK2 is recruited to focal adhesions and activated down-
stream of attachment to extracellular matrix. Finally, we examine the
impact of MEKK2 expression on signaling to propose a mechanism for
MEKK2-dependent tumor cell migration.
2. Materials and methods
2.1. Antibodies and reagents
Anti-MEKK2, anti-MEKK3, and anti-ERK2 antibodies were pur-
chased from Santa Cruz Biotechnology, and anti-vinculin antibodies
were purchased from Sigma. Growth factor reduced Matrigel was
purchased from BD Biosciences. Antibodies speciﬁc to phosphorylated
or total p38, JNK, ERK1/2, ERK5, FAK, and MKK4 were purchased
from Cell Signaling Technology, and anti-MEKK3 antibodies were pur-
chased from Epitomics. Protein A and agarose beads were purchased
from Roche Applied Science. Alexa Fluor®-conjugated phalloidin
and Alexa Fluor®-conjugated secondary antibodies were purchased
from Invitrogen. Fibronectin and collagen were purchased from
Sigma. Horseradish peroxidase conjugated secondary donkey anti-
rabbit was purchased from Jackson ImmunoResearch. Horseradish
peroxidase conjugated secondary sheep anti-mouse was purchased
from Amersham-GE Health. BIX02189 was purchased from Selleck
Chemicals, and XMD 8-92 from TOCRIS Bioscience.2.2. Plasmid vectors
The cDNA vectors encoding wild-type HA-tagged MEKK2
and kinase-inactive mutant MEKK2 (K385M) cloned into pCMV5
were previously described [18]. FLAG-tagged MEKK2 kinase domain
(amino acids 357–619) was produced by PCR and cloned into
pCDNA3. The vector encoding inactive GST-MKK4 was a generous
gift of Dr. Ajay Rana (Loyola University Chicago). Lentiviral vectors
encoding MEKK2 shRNA were purchased from Open Biosystems
(ThermoScientiﬁc).
2.3. Cell culture and transfection
MDA-MB 231 breast tumor cells stably expressing MEKK2 shRNA
cells were described previously [19]. Brieﬂy, stable lines were created
by infecting cells with lentivirus encoding either of two distinct MEKK2
shRNA sequences (OpenBiosystems clone IDs TRCN0000002043 and
TRCN0000002045), followed by selection with puromycin-containing
growth media (2 μg/ml) where indicated. HEK-293T cells were
purchased from A.T.C.C. All cells were cultured in DMEM (Dulbecco's
modiﬁed Eagle's medium) (Invitrogen) containing 10% (v/v) fetal
bovine serum (Atlanta Biologicals) at 37 °C and maintained in 5%
CO2 in a humidiﬁed atmosphere. All transfections were conducted
using Lipofectamine Plus (Invitrogen) as per the manufacturer's
recommendations.
2.4. Immunoﬂuorescence
MDA-MB 231 cells expressing either empty vector or MEKK2-
speciﬁc shRNAwere seeded ontomatrix protein-coated glass coverslips
as follows: sterile washed coverslips were incubated in phosphate-
buffered saline (PBS) containing matrix proteins (20 μg/ml of ﬁbronec-
tin, 100 μg/ml of Matrigel and 20 μg/ml collagen) for 1 h at 37 °C, then
were removed and allowed to dry. Cultured cells were dispersed with
enzyme-free cell dissociation buffer (Life technologies), washed and
resuspended in serum-free growth media before seeding into culture
dishes containing the coated coverslips and allowed to adhere for
the indicated times. Cells were then ﬁxed in methanol-free 4% (w/v)
formaldehyde (Thermo Scientiﬁc) in PBS for 15 min. Following three
PBS washes, the cells were permeabilized for 15 min with 0.1% Triton
X-100 in PBS. After washing, the coverslips were blocked in 5% (v/v)
goat serum/PBS for 1 h at room temperature (23 °C), then incubated
with either anti-MEKK2 or anti-vinculin antibodies as indicated
overnight at 4 °C. After three washes, the coverslips were incubated
with Alexa Fluor® 488-conjugated anti-rabbit, Alexa Fluor® 594-
conjugated anti-mouse and Alexa Fluor® 647-conjugated phalloidin
(Invitrogen) in blocking solution overnight at 4 °C. Following
washing, cells were mounted in Fluoro-Gel (Electron Microscopy
Services). Images were acquired using 60× objective on an Olympus
IX81 microscope.
2.5. Quantiﬁcation of protein colocalization
MDA-MB 231 cells seeded on glass coverslips coated with Matrigel
were ﬁxed and incubatedwith anti-vinculin and anti-MEKK2 antibodies
as described above. A minimum of 12 sequential Z-stack images were
taken at 0.5 μm intervals on a DeltaVision microscope and deconvolved
using softWoRx software (Applied Precision). The deconvolved images
were rendered in three-dimensions using Imaris software (Bitplane
Inc.). Surfaces were then constructed around regions of high vinculin
concentration using a constant ﬂuorescence threshold for vinculin and
a minimum volume of 0.4 μm3 using the Surface Finder function of the
software and was globally applied to all images. Total ﬂuorescence in-
tensity of MEKK2 within the deﬁned focal adhesion surfaces was calcu-
lated by the program and reported as intensity units/μm3. Statistical
correlationwas calculatedusing the Pearson Correlation Coefﬁcient test.
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The total number and associated area of focal adhesions detected
within ﬁxed MDA-MB 231 cells seeded on FN (20 μg/ml) and stained
with anti-vinculin antibodies were quantiﬁed with ImageJ software
using a procedure adapted from a previously described approach
[20,21]. Brieﬂy, center region of cells containing the nucleus and
majority of the cell body was manually traced and masked. Total cells
analyzed are n = 48 control MDA-MB 231 cells and n = 46 MDA-MB
231 cells with stable MEKK2 knockdown. The detection threshold for
pixel intensity was initially set by the program to distinguish focal
adhesions from background ﬂuorescence and was globally applied to
all images thereafter. The resulting pixelswere then converted to binary
images and the number and area of focal adhesions were determined
using the “Analyze Particles” function in ImageJ. The datawere analyzed
and graphed using Prism 4 from GraphPad Software, Inc. (La Jolla, CA).
The statistical signiﬁcance was calculated using unpaired t-test.
2.7. Attachment assay
Cells were seeded on FN-coated 96-well plates (20 μg/ml) and
incubated undisturbed at 37 °C for 30 min. The plates were then
vortexed at 2000 rpm for 30 s, after which the media and unattached
cells were removed. Attached cells were ﬁxed in methanol and images
were acquired with an inverted microscope equipped with a camera
and Micron imaging software. Images of at least four wells taken prior
and post-vortexing were counted using ImageJ v1.46h (NIH). The data
were analyzed and graphed using Prism 4 from GraphPad Software,
Inc. (La Jolla, CA) and statistical signiﬁcance was calculated using
unpaired t-test.
2.8. Spreading assay
Cells were seeded on FN-coated 96-well plates (20 μg/ml) and
incubated undisturbed at 37 °C for 2 h to allow for adherence and
spreading. Media were then removed and cells were ﬁxed in methanol.
Images were acquired using an inverted microscope equipped with a
camera and Micron imaging software. The perimeter of each cell was
traced using ImageJ v1.46h (NIH) to calculate the surface area; cells
sharing an edge or more were excluded. Approximately 600 individual
cells were measured in images from at least four wells. The data
were analyzed and graphed using Prism 4 from GraphPad Software,
Inc. (La Jolla, CA) and statistical signiﬁcance was calculated using the
Mann–Whitney U-test.
2.9. In vitro wound healing assay
The procedure was adapted and modiﬁed from one previously de-
scribed [22]. Brieﬂy, cells were seeded and incubated until conﬂuent.
The cell layer was gently wounded using a pipet tip, washed and incu-
bated in complete media at 37 °C for 20 h or less. Imageswere captured
with an invertedmicroscope equippedwith a camera andMicron imag-
ing software then processed using ImageJ v1.46h (NIH) to measure the
distance traveled by the cell front and the rate ofwound closure. The cell
front velocity (v) was calculated as v = d / t, where d is the distance
traveled by the cell front at time t. The percent wound healing rate
(Wr) was calculated as Wr = (1 − (At / A0)) / t, where A0 and At
are the area of the wound at the start of the experiment and at time t
respectively. The data were analyzed and graphed using Prism 4 from
GraphPad Software, Inc. (La Jolla, CA) and statistical signiﬁcance was
calculated using unpaired t-test.
2.10. Immunoblotting
Proteins were separated by SDS-PAGE and transferred onto Protran
nitrocellulose membranes (Whatman). Membranes were blocked in5% (w/v) non-fat dried skimmed milk powder diluted in TBST (20 mM
Tris, 137 mM NaCl and 0.1% Tween-20, adjusted to pH 7.6) or 5%
globulin-free BSA (Sigma) in TBST and incubated in the appropriate
antibody at 4 °C overnight. After extensive washing, the membranes
were then incubated with HRP (horseradish peroxidase)–conjugated
donkey anti-rabbit IgG (Jackson ImmunoResearch) or HRP–sheep
anti-mouse IgG (Amersham-GE Healthcare) secondary antibodies
for 1 h at room temperature. After extensive washing, the targeted
proteins were detected by ECL (enhanced chemiluminescence,
Thermo Scientiﬁc). Where indicated, blots were stripped by treatment
with 2% (w/v) SDS and 100 mM 2-mercaptoethanol in TBS, and then
re-probed with the desired antibodies.
2.11. MEKK2 kinase assay
MDA-MB 231 cells were dispersed, washed in serum-free medium
and seeded on ﬁbronectin-coated plates or mixed in suspension end-
over-end for 20 min. Cells were then lysed in kinase lysis buffer
(20 mM Tris, pH 7.4, 150 mMNaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton
X-100, 1 mMPMSF, 1 mM sodium vanadate, 0.05mMDTT, and 1 μg/ml
leupeptin) and cleared by centrifugation at 13,000 rpm for 10 min at
4 °C and cytosolic cell lysate was collected. 500 μg of total protein
from cell lysates was brought to a volume of 350 μl with lysis buffer
and rotated end-over-end at 4 °C with anti-MEKK2 antibodies over-
night. Protein A beads (15 μl packed volume)were then added to the ly-
sates and were again rotated end-over-end at 4 °C. After 2–4 hours
mixing, the beads were washed twice in lysis buffer and once in kinase
buffer (20mMHEPES, pH 7.5, 10mMMgCl2, 5mM p-nitrophenyl phos-
phate). The beads were then incubated for 20min at 30 °C in 50 μl of ki-
nase buffer supplemented with and 1 μg of puriﬁed MKK4. The mixture
was separated by SDS-PAGE and transferred to nitrocellulose mem-
branes and then immunoblotted with anti-phospho-MKK4 antibodies.
2.12. Transwell migration assay
MDA-MB 231 cells were suspended in serum-free medium contain-
ing eitherMEK5 inhibitor BIX021089 (10 μM), ERK5 inhibitor XMD8-92
(5 μM) or DMSO. Chemotaxis was assessed by Transwell (Corning)
assay, wherein 105 cells were allowed to migrate through a ﬁlter
(8 μm pore) toward 4% serum for 5 h, and then migrating cells were
stained with Wright's stain and counted as previously described [22].
3. Results
3.1. Attachment to ﬁbronectin regulates MEKK2 localization in breast
tumor cells
To deﬁne the location of MEKK2 in breast tumor cells, and thereby
gain insight into possible mechanisms by which MEKK2 promotes
tumor metastasis, we conducted immunoﬂuorescence analysis on
ﬁxed MDA-MB 231 breast tumor cells using antibodies speciﬁc for
MEKK2. In these experiments, we seeded tumor cells onto non-coated
glass coverslips, ﬁxed the cells in formaldehyde and utilized anti-
MEKK2 antibodies to detect endogenous MEKK2 protein. In addition,
we also seeded cells onto ﬁbronectin-coated coverslips to enhance at-
tachment and cell spreading prior to ﬁxation. Interestingly, we observed
thatMEKK2 localization changeddramaticallywhen cellswere attached
to ﬁbronectin compared to MEKK2 in cells adhered to uncoated cover-
slips. While MEKK2 was observed in the cytoplasm of cells attached to
uncoated coverslips, we discovered that attachment to ﬁbronectin
induced a marked MEKK2 enrichment in focused areas proximal to
the membrane area attached to ﬁbronectin (Fig. 1). As some of these
MEKK2 enriched areas resembled focal adhesion complexes, we
comparedMEKK2 localizationwith that of the focal adhesion protein
vinculin (Fig. 1). When ﬁbronectin-adhered cells were treated with
both anti-vinculin and anti-MEKK2 antibodies, we observed that
Fig. 1. Cell attachment to matrix protein induces MEKK2 re-distribution. MDA-MB 231 cells seeded on glass coverslips that were either uncoated (ﬁrst row), or coated with collagen
(second row), ﬁbronectin (third row), orMatrigel (fourth row) for 6 h, ﬁxed and stained for immunoﬂuorescence analysis with anti-MEKK2 (green) or anti-vinculin (red) antibodies. Ar-
rowheads indicate areas of MEKK2 localization to focal adhesions. Scale bar represents 20 μm. Images are representative of at least three independent experiments.
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adhesions (Fig. 1). We then examined whether cellular attachment
to other matrix proteins would similarly induce redistribution of
MEKK2 to focal adhesions. We discovered that cell attachment
to Matrigel, but not collagen, also induced MEKK2 to co-localize
with vinculin (Fig. 1). These ﬁndings strongly suggest that MEKK2
redistribution is induced by ligation of a subset of integrin receptors.
Furthermore, as Matrigel consists predominantly of laminin,
collagen IV, and entactin matrix proteins and not ﬁbronectin, these
results indicate that binding of cells to at least two distinct extracel-
lular matrix proteins induces MEKK2 translocalization to focal adhe-
sions. Importantly, we detected a similar MEKK2 localization pattern
in a second breast cancer cell line (BT474), indicating that focal
adhesion-associated MEKK2 was not a cell line-speciﬁc characteris-
tic (data not shown). We concluded that MEKK2 localization in inva-
sive breast tumor cells is consistent with proteins known to regulate
cell adhesion and migration, and therefore we elected to investigate
the role of MEKK2 in these functions.
3.2. MEKK2 is recruited to focal adhesions
Our results suggested that MEKK2 is speciﬁcally recruited to focal
adhesions in response to cellular attachment to Matrigel or ﬁbronectin.To deﬁne the temporal regulation of MEKK2 localization, we ﬁrst iden-
tiﬁed the time required for focal complex formation, then asked when
MEKK2 co-localized in these complexes.Wedetermined by immunoﬂu-
orescence analysis that focal complexeswere detectable in ﬁxed cells as
early as 15 min after attachment to Matrigel. We developed a new
Imaris software-based approach to quantify protein co-localization,
then utilized our technique to quantifyMEKK2 co-localizationwith vin-
culin in focal adhesion complexes over a one-hour time course. Using
vinculin ﬂuorescence as a constant to deﬁne focal adhesion boundaries,
three-dimensional surfaceswere built around vinculin enriched regions
using the Surface Finder function of the Imaris program revealing
conical focal complexes extending from the center out to the periphery
of cells (Fig. 2A-1, 2, 3). We discovered that MEKK2 concentration in
these focal complexes increased over time (Fig. 2B) and is statistically
correlated with incubation time on Matrigel when subjected to a
Pearson Correlation Coefﬁcient test (r (3) = 0.9937, p b 0.005).
Furthermore, vinculin localization in the focal adhesion complexes
precedes that of MEKK2, suggesting that MEKK2 localizes to formed
adhesion complexes and is not required for the formation of focal
adhesions. Altogether, our results strongly suggest thatMEKK2 is recruit-
ed to focal adhesion complexes in response to breast tumor cell attach-
ment to ﬁbronectin or Matrigel, and that ligation of speciﬁc integrin
receptors are required for matrix-induced MEKK2 translocation.
Fig. 2. Quantiﬁcation of MEKK2 colocalization with vinculin in three-dimensional focal
adhesions. (A) Three dimensional rendering of Z-stack images of MDA-MB 231 cells
seeded onMatrigel in theXYplane revealing colocalization ofMEKK2 (green) andvinculin
(red) (A1) or rotated to show focal adhesion volume (A2). Three-dimensional surfaces
(in gray) were constructed around regions of high vinculin ﬂuorescence intensity (A3).
The cell body was subtracted from the image and the colocalized ﬂuorescence signal
was over imposed on the three-dimensional surfaces of focal adhesions. Image is
representative of N140 images taken at four time points. (B) Bar-graph representation of
vinculin and MEKK2 quantiﬁcation showing a signiﬁcant linear correlation of MEKK2
recruitment in focal adhesion with incubation time (r (3) = 0.9937, **p b 0.005).
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not attachment
Cell spreading is dependent upon the dynamics of focal adhesion
formation and disassembly, therefore we asked whether MEKK2
regulates focal adhesion formation and stability. To determine whether
MEKK2 inﬂuences these parameters, we stably knocked down MEKK2
expression utilizing the shRNA vectors we had used previously to
block xenograft metastasis (Fig. 3A) [19]. MEKK2 shows high protein
sequence similarity to another MAP3K called MEKK3, so we conﬁrmed
the speciﬁcity of our MEKK2 shRNA vectors by performing anti-MEKK3immunoblot analysis using lysates from cells with stable MEKK2
knockdown. Although MEKK3 protein shares 55% sequence identity
with MEKK2, the MEKK2 sequences targeted by either shRNA vector
used in this study are not conserved in MEKK3, and as predicted
MEKK2 shRNA did not affect MEKK3 expression (Fig. 3A). These
results strongly suggest that our MEKK2 shRNAs are both very effective
at silencing MEKK2 expression and very speciﬁc for knocking down
only MEKK2. Utilizing immunoﬂuorescence microscopy to detect
endogenous vinculin as a marker of focal adhesions in cells attached
to ﬁbronectin (Fig. 3B), we discovered that both the incidence and
size of focal adhesions are strongly inﬂuenced by MEKK2 expression.
MEKK2 knockdown signiﬁcantly enhanced the number (Fig. 3C)
and area (Fig. 3D) of focal adhesions in breast tumor cells. We next
examined the effect of MEKK2 knockdown on the cell adhesion
parameters of cell surface spread area and attachment. We compared
attachment and spreading on ﬁbronectin of cells with stable MEKK2
knockdown to that of control cells. We found that cell spread area
is enhanced in cells with stable MEKK2 knockdown (Fig. 4A), and that
cell area was rescued to control levels by expression of shRNA-
resistant MEKK2 (add-back). In contrast, MEKK2 knockdown did not
alter the ability of cells to attach to ﬁbronectin-coated plates (Fig. 4B)
indicating that the enhanced spreading of surface area in cells with
MEKK2 knockdown was not due to increased or accelerated cell
attachment. Furthermore, when we knocked down MEKK2 expression
in SKBR3 breast tumor cells, we observed similar effects of MEKK2
knockdown on cell area (data not shown), indicating that MEKK2
knockdown-associated cell spreading is not limited to MDA-MB 231
cells, and therefore is not a cell line-speciﬁc effect of MEKK2 shRNA.
Altogether, these results suggest that MEKK2 activity promotes focal
adhesion turnover in invasive breast tumor cells.
3.4. MEKK2 knockdown inhibits breast tumor cell migration
Adhesion is an integral component of cell migration, therefore to
determine whether MEKK2 inﬂuences cell migration, we compared
the migration of cells with stable MEKK2 knockdown to that of control
cells. We utilized in vitro wound-healing assays to assess cell migration
as a function of the time required for a conﬂuent culture of cells to ﬁll
the area cleared of cells by “wounding”with a pipet tip (wound-healing
rate). Strikingly, we observed that while cells stably transfected with
empty vector (control) had nearly ﬁlled the wound by 20 h, cells stably
expressing either of two distinct MEKK2 shRNAs showed a markedly
reduced wound healing rate (Fig. 5A, B). We discovered that cells with
stable MEKK2 knockdown consistently displayed prolonged wound-
healing time compared to control cells, indicating a clear reduction in
directed cell migration of MEKK2-deﬁcient cells (Fig. 5B). Since cell sur-
face area can inﬂuence scratch assay results independently of migration
rate, we conﬁrmed our ﬁndings by quantifying the velocity of cell
movement along the wound edge (cell front), and found that silencing
MEKK2 expression was associated with a reduced cell front velocity
(Fig. 5C). Furthermore, re-expression of MEKK2 in cells with stable
knockdown (add-back cells) rescued cell migration to a level similar
to controls, thereby conﬁrming that the reduced migration was due
to a speciﬁc MEKK2 knockdown and not an off-target shRNA effect
(Fig. 5B). Consistent with these ﬁndings, cell-front velocity was
also partially rescued when MEKK2 expression was restored (Fig. 5C).
Taken together, these data strongly suggest that MEKK2 regulates cell
migration in MDA-MB 231 cells.
3.5. Attachment to ﬁbronectin activates MEKK2
Our data strongly suggest that MEKK2 activity is subject to spatial
and temporal regulation by ﬁbronectin. We asked whether attachment
to ﬁbronectin was sufﬁcient to activate MEKK2 by performing semi-
quantitative kinase assays with MEKK2 puriﬁed from cells seeded
on ﬁbronectin. Using recombinant inactive MKK4 as a substrate,
Fig. 3.MEKK2 knockdown stabilizes focal adhesions. (A) Immunoblot of MDA-MB 231 lysates displaying expression of MEKK2 (upper panel), MEKK3 (middle panel), and total ERK2 as a
loading control (lowerpanel) from control cells, cells treatedwithMEKK2 shRNA#s 1 and 2, orMEKK2 shRNAwith stably expressed shRNA-resistantMEKK2 (Add-back). (B) Fluorescence
microscopy with anti-vinculin antibodies was used to detect focal adhesions in MDA-MB 231 cells attached to ﬁbronectin. Representative images after 16 h of attachment showing
vinculin-associated focal adhesions in control cells (upper panel, left) or cells with MEKK2 shRNA (upper panel, right). Original images were converted to binary images (lower panel)
for analysis. (C) Quantiﬁcation of number of focal adhesions per cell, and (D) mean area of individual focal adhesions after attachment to ﬁbronectin for 5 h and 16 h in MDA-MB 231
cells. The data represented in the graphs was derived from at least three independent experiments. Total cells analyzed are n = 48 control MDA-MB 231 cells and n = 46 MDA-MB
231 cells with stable MEKK2 knockdown (D). The data represented in the graphs was derived from at least three independent experiments. *p b 0.05, **p b 0.01, ***p b 0.001.
Scale bar represents 10 μm.
Fig. 4.MEKK2 regulates the surface area of spreading cells. (A) MDA-MB 231 control cells, cells treated with MEKK2 shRNAs, or MEKK2 shRNA with stably expressed YFP-MEKK2
(Add-back) were plated on ﬁbronectin-coated cell culture plates for 2 h. (B) Quantiﬁcation of the impact of MEKK2 knockdown on cell spread area. (C) MEKK2 knockdown did
not have an effect on MDA-MB231 cells in attachment assays on ﬁbronectin after 30 min. The results were normalized to control and compiled from at least three independent
experiments. ***p b 0.001.
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Fig. 5. Silencing MEKK2 expression inhibits tumor cell migration. (A) In vitro wound healing assay showing effect on migration parameters of stable MEKK2 expression knockdown.
The blue lines indicate the cell front at the beginning of the assay (0 h) and the red line indicates the cell front at the end of the assay (20 h). ImageJwas used tomeasure thewound healing
rate (B) and cell-front velocity of cellsmigrating into thewound (C) on non-coated cell culture plastic plates. The resultswere normalized to control, andwere compiled from at least three
independent experiments. *p b 0.05, ***p b 0.001.
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by immunoprecipitated MEKK2 with phosphor-speciﬁc MKK4
antibodies (phospho-MKK4 S257/T261). We discovered that endoge-
nous MEKK2 was activated by cellular attachment to ﬁbronectin,
compared to MEKK2 puriﬁed from cells in suspension (Fig. 6). This
result indicate that attachment to ﬁbronectin and so the activation of
its receptor was sufﬁcient to activate MEKK2.
3.6. MEKK2 regulates ﬁbronectin-induced ERK5 and FAK phosphorylation
Next we examined the functional consequences of ﬁbronectin
attachment on signaling proteins downstream of MEKK2 by immuno-
blot analysis using phospho-speciﬁcMAPK antibodies as surrogate indi-
cators of MAPK activation. Integrin ligation clearly activates signaling
leading toMEKK2-dependent phosphorylation of ERK5, but surprisingly
we did not detect ﬁbronectin-induced JNK activity-associated phos-
phorylation (Fig. 7A). Similarly, we did not detect p38 phosphorylation
in response to attachment to ﬁbronectin. Activity-associated ERK1/2
phosphorylation was consistently detectable although variable, and
pERK1/2 from integrin bound cells was usually similar to that of the
controls. This consistent high pERK1/2 background level was likely
due to the fact that MDA-MB 231 cells express mutated active KRAS.
Regardless, pERK1/2 levels in either untreated or ﬁbronectin-bound
cells were independent of MEKK2 expression. Collectively, these data
indicate that attachment to ﬁbronectin induces signaling that leads to
activation of MEKK2 and ERK5, but not JNK.
To gain additional insight into the mechanism by which MEKK2
expression inﬂuences cell migration, we examined the effect of
MEKK2 knockdown on ﬁbronectin-induced FAK autophosphorylation.FAK autophosphorylates tyrosine residue 397 (Y397), that leads to
association with multiple proteins and can be used as a surrogate
assay for FAK activation. As expected, our immunoblot analysis showed
FAK autophosphorylation in response to ﬁbronectin compared to FAK
from cells kept in suspension. However, we observed that ﬁbronectin-
induced Y397 phosphorylation was reduced in cells with stable
MEKK2 knockdown, indicating that FAK autophosphorylation is partly
MEKK2-dependent (Fig. 7B). To test this hypothesis, we examined
whether ERK5 activity was required for MDA-MB 231 cell migration.
Using a modiﬁed Boyden chamber assay, we tested to determine the
impact of ERK5 inhibition on chemotaxis induced by serumwith a spe-
ciﬁc ERK5 inhibitor XMD 8-92 (x). We observed that ERK5 inhibition
with either XMD 8-92 or MEK5 inhibitor BIX02189 signiﬁcantly
reduced the ability of cells to migrate (Fig. 7C, Supplemental Fig. 1),
inhibiting chemotaxis to an extent similar to MEKK2 knockdown
(Fig. 5B). As MEKK2 phosphorylates and activates MEK5, which,
in turn phosphorylates and activates ERK5, these data indicate that
MEK5 regulates breast tumor cell chemotaxis, and suggest that the
MEKK2 regulatesMDA-MB231 cellmigration, at least in part, by control
of ERK5 activity. To address this possibility, we expressed constitutively
active MEKK2 (MEKK2 kinase domain, amino acids 357–619) [26] in
cells with MEKK2 knockdown and repeated the chemotaxis assays in
the presence of the inhibitors. We found that stable expression of
the MEKK2 kinase domain was associated with an increase in serum-
induced chemotaxis, and that this increase was partially blocked by
treatment with either an ERK5 inhibitor (XMD 8-92) or a MEK5 inhibi-
tor (BIX02189). These data suggest that MEKK2 activity promotes
MDA-MB 231 cell chemotaxis via amechanism that is partly dependent
upon ERK5 activity. Taken together, these results indicate that both
Fig. 6. Adhesion to ﬁbronectin activates MEKK2 in MDA-MB 231 cells. (A) In vitro kinase
assay using anti-phospho-MKK4 (S257/T261) immunoblot to reveal phosphorylation of
recombinant MKK4 by endogenous MEKK2 immunoprecipitated from MDA-MB 231
cells (upper panel). Cells were either adhered to ﬁbronectin-coated plastic cell culture
plate (FN) for 20 min or maintained in suspension (Susp) for 20 min prior to lysis.
The substrate alonewithout immunoprecipitatedMEKK2 (cont) is included for comparison.
MEKK2 was immunoprecipitated as shown by immunoblot (middle panel), and
recombinant MKK4 substrate loading is detected by Coomassie stain (bottom panel).
(B) Bar-graph showing relative MEKK2 kinase activity as determined by immunoblot
densitometry of pMKK4 induced by MEKK2 from ﬁbronectin-attached cells or cells in
suspension of the data shown in (A). The results are representative of at least three
independent experiments, and comparison of the densitometry from these experiments
by paired t test analysis yields a p b 0.05.
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and suggest that MEKK2 signaling contributes to the regulation of FAK
phosphorylation.
4. Discussion
Timely initiation and release of adhesion are required for migration
of both normal cells and cancerous cells. In our previous work, we dem-
onstrated that shRNA-mediated silencing of MEKK2 expression in inva-
sive breast tumor cells resulted in a dramatic reduction in xenograft
metastasis. This metastasis inhibition was speciﬁc to MEKK2 knock-
down, as blockade of six other MAP3K did not show a similar reduction
in the incidence ofmetastasis [19]. ClearlyMEKK2 plays a key role in the
regulation of one ormore tumor cell functions required formetastasis to
occur, but in that study we did not deﬁne the functional role of MEKK2
in breast tumor cells. Indeed, prior to that report, very little evidence
linking MEKK2 to metastasis was available in the literature. Unlike
other MAP3K proteins associated with cancer, such as c-RAF and BRAF
[9], MEKK2 has not been extensively studied and the mechanisms
responsible for MEKK2 activation are largely unknown. Therefore
our goal for this study was to identify MEKK2-dependent tumor
cell function, and thereby gain insight into the mechanisms by which
MEKK2 ablation effectively blocks xenograft metastasis. We found that
MEKK2 expression knockdownwas associated with a signiﬁcant reduc-
tion in directed cell migration, and MEKK2-deﬁcient cells displayed an
increased number and size of visible focal adhesions as well as signiﬁ-
cantly enhanced cell spreading that was inversely related to cell front
velocity and migration (Supplemental Fig. 2). Tumor cell migration is
absolutely required for distant metastasis formation, and our datastrongly suggest that the observed inhibition of metastasis was due, at
least in part, to reduced tumor cell migration in cells in which MEKK2
expression is silenced. It is important to note that, while regulated cell
spreading is an essential component of cell migration, dysregulated,
exaggerated cell spreading associated with enhanced cell adhesion has
been observed to inhibit cell migration [23].
As a result of our investigations, we have uncovered new insights
into the regulation of MEKK2 signaling. For example, we discovered
that the predominantly cytoplasmic MEKK2 translocates to membrane-
proximal areas near focal adhesion complexes in response to cell attach-
ment to ﬁbronectin or Matrigel, an observation that strongly suggests
that integrin ligation initiates the formation of a signaling complex that
recruits MEKK2. Furthermore, during the course of these studies we
have developed a novel technique for quantifying co-localization of
twoproteins usingﬂuorescent images captured fromﬁxed cells. Utilizing
the Surface Builder function of the Imaris software package to analyze
Z-stack sets of immunoﬂuorescence images, we were able to accurately
quantify the colocalization of two proteins, MEKK2 and vinculin, in
three-dimensional space within the cell. As a result, we further report,
for the ﬁrst time, that MEKK2 is recruited to focal adhesion complexes
and that attachment to ﬁbronectin induces MEKK2 activation. To our
knowledge, this report is the ﬁrst to link MEKK2 activation to a speciﬁc
matrix protein. Hence our studies provide a basis for future studies
during which we will deﬁne the composition of the membrane-proximal
signaling complex necessary for MEKK2 recruitment and activation.
Our observation that ﬁbronectin induces MEKK2 activation that
is detectable from the analysis of whole cell lysates was somewhat a
surprising result given that only a subset of MEKK2 was translocated
to the membrane focal adhesion complexes, whereas some MEKK2
remained localized to the cytoplasm. We postulate that the membrane-
associated MEKK2 is active, therefore it is possible that MEKK2 localized
to focal adhesions is differently regulated than cytoplasmic MEKK2.
Other kinases, including the known MEKK2 regulator Src [8], localize to
focal adhesions, and thus when it is recruited to focal adhesion protein
complexesMEKK2may be subject to activation by Src and other kinases.
The location of potential regulatory phosphorylation sites within
MEKK2 remains largely undeﬁned, and aside from the MEKK2
carboxyl-terminal kinase domain and the amino-terminal PB1
domain, the function of most of the remaining MEKK2 sequence
remains unknown. A recent report from Matitau and colleagues re-
veals that serine phosphorylation promotes an interaction between
MEKK2 and 14-3-3 that negatively regulates MEKK2 activity [25],
and our analysis of the MEKK2 peptide sequence reveals additional
potential phosphorylation sites, as well as proline-rich sequences
that may serve as SH3-binding proline-rich motifs. Thus much
of MEKK2 regulation and function remains to be deﬁned. Indeed,
as PB1 domains serve as docking ports for other PB1 domain-
containing proteins [18], it is possible that MEKK2 performs a scaffold-
ing function [24] within focal adhesion protein complexes. As MEKK2
interaction with MEK5 is mediated by their respective PB1 domains,
MEKK2 serves as both an activator of ERK5 signaling and a scaffold
for ERK5 activation complexes. Based on our results, we would postu-
late that this scaffold function would promote ERK5-dependent
phosphorylation of FAK and other ERK5 substrates. Our future
work will investigate the interactions between MEKK2 and focal adhe-
sion proteins that mediate MEKK2 localization, activation and function
within focal adhesion complexes.
Based on our results, we conclude that integrin receptor ligation
to ﬁbronectin initiates signaling that leads to MEKK2 activation and
recruitment to focal adhesions. Consistent with these conclusions, we
report thatMEKK2 knockdown is associatedwith focal adhesion stabili-
zation and inhibited cell migration. However, the mechanism by which
MEKK2 is recruited to focal adhesions was not explored in this project
and is unclear at present. Our future studies will examine the nature
of the MEKK2-associated protein complex at focal adhesions as an
essential step in understanding how MEKK2 integrates into focal
Fig. 7.MEKK2 regulates FN-induced signaling. (A andB)MDA-MB231 control cells and cellswith stableMEKK2 knockdownwere seeded on uncoated culture plates (not treated) or plates
coatedwith ﬁbronectin. Positive control cells for JNK, ERK5, p38 or ERK1/2 activationwere exposed to 0.2M sorbitol for 15min. (B) Immunoblots showing the level of ﬁbronectin-induced
FAK Y397 phosphorylation (upper panel) inMDA-MB 231 control cells and in cells with stableMEKK2 knockdown. Total FAK immunoblot (middle panel) shows equal protein content of
test lanes and MEKK2 immunoblot (bottom panel) conﬁrms MEKK2 knockdown. (C and D) Graphical representation of transwell migration assays of MDA-MB 231 cells treated with
vehicle (DMSO), BIX02189 MEK5 inhibitor (10 μM) or ERK5 inhibitor XMD 8-92 (5 μM) during the 5 hour migration period. (D) Serum-induced chemotaxis of MDA-MB 231 cells that
stably express activated MEKK2 (357–619) is compared to that of MDA-MB 231 cells that express endogenous MEKK2 (control) or cells that express MEKK2 (357–619) but migrated
in the presence of the inhibitors. Results are compiled from three independent experiments.
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activity in vivo. As speciﬁc MEKK2 inhibitors are not available at
present, characterizing these functional MEKK2 interactions may reveal
potential therapeutic targets for treatment of pathologies associated
with inappropriate cell migration, including, but not limited to, breast
cancer metastasis.
In summary, our ﬁndings show that cellular attachment to
extracellular proteins regulates MEKK2 activity and distribution,
and links MEKK2 to control of breast tumor cell migration. Our study
is the ﬁrst to provide evidence that MEKK2 regulates breast tumor cell
adhesion complex stability and migration, and controls ﬁbronectin-
induced FAK and ERK5 activation.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.01.029.
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